Factors associated with grade II to IV aGVHD incidence: univariate analysis of potential prognostic factors on the incidence rate of grade II to IV aGVHD
| Factor . | All patients, % (no.) . | HLA 10 of 10 match patients, % (no.) . | HLA < 10 of 10 match patients, % (no.) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| aGVHD . | No aGVHD . | P . | aGVHD . | No aGVHD . | P . | aGVHD . | No aGVHD . | P . | |
| Age > 60 y | 42 (23/54) | 44 (81/182) | .5 | 42 (19/45) | 40 (51/127) | .94 | 44 (4/9) | 54 (30/55) | .4 |
| Pentostatin GVHD prophylaxis | 44 (27/61) | 44 (77/175) | .79 | 39 (17/44) | 41 (53/128) | .95 | 59 (10/17) | 51 (24/47) | .65 |
| Fludarabine-based regimen | 42 (89/213) | 65 (15/23) | .002* | 39 (62/159) | 61 (8/13) | .53 | 50 (27/54) | 70 (7/10) | .04* |
| Reduced intensity conditioning | 35 (34/97) | 50 (70/139) | .02 | 32 (24/74) | 47 (46/98) | .05* | 43 (10/23) | 58 (24/41) | .25 |
| HLA 10/10 | 40 (70/172) | 53 (34/64) | .05 | ||||||
| Two-DPB1 mismatch | 55 (33/60) | 39 (25/63) | .04* | 37 (8/52) | 51 (12/27) | .02 | 65 (11/17) | 46 (7/15) | .32 |
| MICA GvH mismatch | 80 (16/20) | 40 (88/216) | < .001* | 75 (6/8) | 39 (64/164) | .03* | 83 (10/12) | 46 (24/52) | .03* |
| Remission at transplantation | 41 (42/102) | 46 (62/134) | .55 | 32 (25/77) | 47 (45/95) | .03 | 68 (17/25) | 43 (17/39) | .07 |
| Factor . | All patients, % (no.) . | HLA 10 of 10 match patients, % (no.) . | HLA < 10 of 10 match patients, % (no.) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| aGVHD . | No aGVHD . | P . | aGVHD . | No aGVHD . | P . | aGVHD . | No aGVHD . | P . | |
| Age > 60 y | 42 (23/54) | 44 (81/182) | .5 | 42 (19/45) | 40 (51/127) | .94 | 44 (4/9) | 54 (30/55) | .4 |
| Pentostatin GVHD prophylaxis | 44 (27/61) | 44 (77/175) | .79 | 39 (17/44) | 41 (53/128) | .95 | 59 (10/17) | 51 (24/47) | .65 |
| Fludarabine-based regimen | 42 (89/213) | 65 (15/23) | .002* | 39 (62/159) | 61 (8/13) | .53 | 50 (27/54) | 70 (7/10) | .04* |
| Reduced intensity conditioning | 35 (34/97) | 50 (70/139) | .02 | 32 (24/74) | 47 (46/98) | .05* | 43 (10/23) | 58 (24/41) | .25 |
| HLA 10/10 | 40 (70/172) | 53 (34/64) | .05 | ||||||
| Two-DPB1 mismatch | 55 (33/60) | 39 (25/63) | .04* | 37 (8/52) | 51 (12/27) | .02 | 65 (11/17) | 46 (7/15) | .32 |
| MICA GvH mismatch | 80 (16/20) | 40 (88/216) | < .001* | 75 (6/8) | 39 (64/164) | .03* | 83 (10/12) | 46 (24/52) | .03* |
| Remission at transplantation | 41 (42/102) | 46 (62/134) | .55 | 32 (25/77) | 47 (45/95) | .03 | 68 (17/25) | 43 (17/39) | .07 |
P values remain significant in multivariate analysis.